Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms.


Journal

Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 15 06 2019
accepted: 13 08 2019
pubmed: 28 8 2019
medline: 21 3 2020
entrez: 28 8 2019
Statut: ppublish

Résumé

Internet-based cognitive behavioral therapy (iCBT), with and without therapist support, is effective in reducing treatment-induced menopausal symptoms and perceived impact of hot flushes and night sweats (HF/NS) in breast cancer survivors. The aim of the current study was to evaluate the cost-utility, cost-effectiveness, and budget impact of both iCBT formats compared to a waiting list control group from the Dutch healthcare perspective. A Markov model was constructed with a 5-year time horizon. Costs and health outcomes were measured alongside a randomized controlled clinical trial and included quality-adjusted life years (QALYs), overall levels of menopausal symptoms, and perceived impact of HF/NS. Uncertainty was examined using probabilistic and deterministic sensitivity analyses, together with a scenario analysis incorporating a different perspective. iCBT was slightly more expensive than the waiting list control, but also more effective, resulting in incremental cost-utility ratios of €23,331/QALY and €11,277/QALY for the guided and self-managed formats, respectively. A significant reduction in overall levels of menopausal symptoms or perceived impact of HF/NS resulted in incremental costs between €1460 and €1525 for the guided and €500-€753 for the self-managed format. The estimated annual budget impact for the Netherlands was €192,990 for the guided and €74,592 for the self-managed format. Based on the current trial data, the results indicate that both guided and self-managed iCBT are cost-effective with a willingness-to-pay threshold of well below €30,000/QALY. Additionally, self-managed iCBT is the most cost-effective strategy and has a lower impact on healthcare budgets.

Identifiants

pubmed: 31451978
doi: 10.1007/s10549-019-05410-w
pii: 10.1007/s10549-019-05410-w
pmc: PMC6817759
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

573-585

Subventions

Organisme : KWF Kankerbestrijding
ID : 2014-6788

Références

Health Qual Life Outcomes. 2009 Mar 31;7:27
pubmed: 19335878
J Clin Oncol. 1996 May;14(5):1718-29
pubmed: 8622093
Acta Oncol. 2011 Feb;50(2):212-22
pubmed: 21231783
BMC Health Serv Res. 2013 Jun 15;13:217
pubmed: 23768141
Bull World Health Organ. 2015 Feb 1;93(2):118-24
pubmed: 25883405
Climacteric. 2006 Feb;9(1):49-58
pubmed: 16428125
Psychooncology. 2004 Nov;13(11):769-78
pubmed: 15386641
Pharmacoeconomics. 2000 May;17(5):445-59
pubmed: 10977387
Eur J Cancer. 2010 May;46(8):1382-91
pubmed: 20359886
Oncol Nurs Forum. 1999 Sep;26(8):1311-7
pubmed: 10497770
Br J Clin Psychol. 1995 Nov;34(4):589-99
pubmed: 8563666
J Clin Epidemiol. 1998 Nov;51(11):1055-68
pubmed: 9817123
Lancet. 2005 Sep 3-9;366(9488):818-24
pubmed: 16139656
Menopause. 2017 Jul;24(7):762-767
pubmed: 28195994
Menopause. 2014 Oct;21(10):1075-81
pubmed: 24618765
J Comp Eff Res. 2015 Sep;4(5):485-504
pubmed: 26490020
J Natl Cancer Inst. 2012 Mar 7;104(5):386-405
pubmed: 22271773
Qual Life Res. 2018 Aug;27(8):2077-2086
pubmed: 29740782
BMC Cancer. 2016 Nov 25;16(1):920
pubmed: 27887581
BMJ. 1996 Feb 17;312(7028):426-9
pubmed: 8601116
Psychooncology. 2016 Jan;25(1):51-7
pubmed: 26110652
J Clin Oncol. 2019 Apr 1;37(10):809-822
pubmed: 30763176
J Psychosom Obstet Gynaecol. 2017 Sep;38(3):226-235
pubmed: 27583832
JAMA. 2006 May 3;295(17):2057-71
pubmed: 16670414
Pharmacoeconomics. 2013 Jul;31(7):537-49
pubmed: 23620213
Menopause. 2012 Jul;19(7):749-59
pubmed: 22336748
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
N Engl J Med. 2001 Jun 28;344(26):1997-2008
pubmed: 11430330
Ann Pharmacother. 2013 Mar;47(3):380-7
pubmed: 23463742
Br J Psychiatry. 2005 Jan;186:11-7
pubmed: 15630118
J Clin Oncol. 2012 Nov 20;30(33):4124-33
pubmed: 23045575
J Cancer Surviv. 2015 Mar;9(1):126-35
pubmed: 25179578
Value Health. 2014 Jan-Feb;17(1):5-14
pubmed: 24438712
Value Health. 2007 Sep-Oct;10(5):336-47
pubmed: 17888098
Breast Cancer Res Treat. 1999 May;55(2):189-99
pubmed: 10481946
Value Health. 2008 Dec;11(7):1131-43
pubmed: 18489495
Psychooncology. 2001 Nov-Dec;10(6):511-20
pubmed: 11747063
Pharmacoeconomics. 2002;20(7):443-54
pubmed: 12093300
Cancer. 2007 Mar 1;109(5):832-9
pubmed: 17243168
Value Health. 2012 Sep-Oct;15(6):812-20
pubmed: 22999130
J Clin Oncol. 2011 Oct 10;29(29):3862-8
pubmed: 21911720
Med Care. 2003 May;41(5):582-92
pubmed: 12719681
Qual Life Res. 2007 Aug;16(6):1073-81
pubmed: 17468943
Eur J Health Econ. 2018 Jul;19(6):861-870
pubmed: 28871490
Psychooncology. 2004 Mar;13(3):147-60
pubmed: 15022150
Lancet Oncol. 2012 Mar;13(3):309-18
pubmed: 22340966
Hematol Oncol Clin North Am. 2013 Aug;27(4):805-27, ix
pubmed: 23915746
Breast Cancer Res Treat. 2012 Jul;134(2):459-78
pubmed: 22689091
Int J Technol Assess Health Care. 2012 Apr;28(2):152-8
pubmed: 22559757
Lancet Oncol. 2013 Nov;14(12):1165-74
pubmed: 24131614

Auteurs

Joost G E Verbeek (JGE)

Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, P.O. Box 90203, 1006 BE, Amsterdam, The Netherlands.
Department of Health Technology and Services Research, Unveristy of Twente, Enschede, The Netherlands.

Vera Atema (V)

Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, P.O. Box 90203, 1006 BE, Amsterdam, The Netherlands.

Janne C Mewes (JC)

Panaxea, Amsterdam, The Netherlands.

Marieke van Leeuwen (M)

Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, P.O. Box 90203, 1006 BE, Amsterdam, The Netherlands.

Hester S A Oldenburg (HSA)

Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Marc van Beurden (M)

Department of Gynecology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Myra S Hunter (MS)

Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK.

Wim H van Harten (WH)

Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, P.O. Box 90203, 1006 BE, Amsterdam, The Netherlands.
Department of Health Technology and Services Research, Unveristy of Twente, Enschede, The Netherlands.

Neil K Aaronson (NK)

Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, P.O. Box 90203, 1006 BE, Amsterdam, The Netherlands.

Valesca P Retèl (VP)

Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, P.O. Box 90203, 1006 BE, Amsterdam, The Netherlands. v.retel@nki.nl.
Department of Health Technology and Services Research, Unveristy of Twente, Enschede, The Netherlands. v.retel@nki.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH